












doi:10.101Impact of Recipient Statin Treatment
on Graft-versus-Host Disease after Allogeneic
Hematopoietic Cell Transplantation
Marcello Rotta,1 Barry E. Storer,1,2 Rainer Storb,1,3
Paul J. Martin,1,3 Mary E. D. Flowers,1,3 Miwa S. Vernon,1 Amanda Peffer,1,3
David G. Maloney,1,3 H. Joachim Deeg,1,3
Brenda M. Sandmaier,1,3 Frederick R. Appelbaum,1,3 Marco Mielcarek1,3We retrospectively analyzed outcomes among 1206 patients with hematologic malignancies who had
hematopoietic cell transplantation (HCT) from HLA-identical siblings (n 5 630) or HLA-matched unrelated
donors (n 5 576) at a single institution between 2001 and 2007 for a correlation between recipient statin
use and risk of graft-versus-host disease (GVHD). Among recipients with cyclosporine-based postgrafting im-
munosuppression (n5 821), statin use at the time of transplant (6%) was associated with a decreased risk of
extensive chronicGVHD (cGVHD) (multivariate hazard ratio [HR], 0.62; 95%confidence interval [CI], 0.4-1.0;
P5.05) and an increased risk of recurrent malignancy (HR, 1.75; 95%CI, 1.0-3.0; P5.04). Recipient statin use,
however, had no apparent impact on the risks of cGVHD and recurrent malignancy among recipients given
tacrolimus-based immunosuppression (n5385; 8% statin treated). Risksof acuteGVHD, nonrelapsemortality,
and overall mortality were not significantly affected by recipient statin use. Hence, recipient statin treatment at
the time of allogeneic HCTmay decrease the risk of cGVHD in patients with cyclosporine-based immunosup-
pression, but at the expense of a compromised graft-versus-tumor effect.
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In recent years, statins have been shown to affect
immune responses through a variety of mechanisms, in-
cluding induction of T cell hyporesponsiveness by inter-
ference with intracellular signaling pathways, expansion
of regulatory T cells (Tregs), polarization toward an
anti-inflammatory T cell phenotype (Th2), and downre-
gulation of antigen-presenting cell function [1-7].
More recent studies have shown that statins
protect against graft-versus-host-disease (GVHD)
after hematopoietic cell transplantation (HCT) [7-10].Division of Clinical Research, Fred Hutchinson Cancer
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mismatched murine HCT model, for example,
donor or recipient treatment with statin a resulted in
significantly reduced acute GVHD (aGVHD) lethality
[7]. These findings were corroborated by Wang et al.
[11], who found that lovastatin, but not pravastatin,
prevented GVHD by virtue of interfering with LFA1-
mediated homing of T cells to GVHD target organs.
In a retrospective analysis of 67 patients who had re-
ceived HLA-matched or mismatched related or unre-
lated allografts, Hamadani et al. [8] described a trend
toward decreased risk of grade II-IV aGVHD among
the 10 recipients who were treated with statins at the
time of HCT, but definitive conclusions were limited
by the small sample size [8].
In a retrospective analysis of 567 consecutive recip-
ients of allografts from HLA-identical sibling donors,
we recently reported that donor statin use was associ-
ated with profound protection against grades III-IV
aGVHD [9]. Because our analysis of the potential
impact of recipient statin use on GVHD was limited
by the sample size in the previous study, we now ana-
lyzed data from both related and unrelated transplants.
A similarly broad examination of donor statin use on1463
Table 1. Recipient, Donor, and Transplant Characteristics








1464 Biol Blood Marrow Transplant 16:1463-1466, 2010M. Rotta et al.GVHD was not possible because medication data for
unrelated donors are not available. We found that,
among recipients with cyclosporine (CsA)-based im-
munosuppression, statin use was associated with an ap-
proximately 40% reduced risk of chronic GVHD
(cGVHD) without affecting the risk of aGVHD.Recipient Characteristics n (%) n (%)
Median age,
range (years)
52, 20-79 60, 31-72 <.001
Age >50 years 627 (55) 68 (89) <.001
Sex, female 513 (45) 16 (21) <.001
Disease
AML 417 (37) 24 (32) ns
MDS 284 (25) 21 (28)
NHL 112 (10) 9 (12)
CML 88 (8) 7 (9)
MM 69 (6) 3 (4)
ALL 77 (7) 4 (5)
CLL 47 (4) 6 (8)
HD 17 (1) 0 (0)
Other 19 (2) 2 (3)
Disease risk*
Standard 541 (48) 31 (41) ns
High 589 (52) 45 (59)
Donor characteristics
HLA-identical sibling 602 (53) 28 (37) .006
-matched unrelated 528 (47) 48 (63)
Median age,
range (years)
43, 18-80 42, 19-83 ns
Age >50 years 331 (29) 26 (34) ns
Sex, female 509 (45) 34 (45) ns
Female donor
with male recipient
113 (10) 10 (13) ns
Transplant characteristics
Conditioning
Myeloablative 689 (61) 31 (41) <.001
Nonmyeloablative 441 (39) 45 (59)
Stem cell source
Mobilized blood cells 1031 (91) 73 (96) ns




773 (71) 48 (63) ns
Tacrolimus with MTX
or MMF‡
357 (29) 28 (37)
ATG 78 (7) 6 (8) ns
ALL indicates acute lymphoblastic leukemia; AML, acute myelogenous
leukemia; ATG, antithymocyte globulin; BM, bone marrow; CLL, chronic
lymphocytic leukemia; CML, chronic myelogenous leukemia; GVHD,
graft-versus-host disease; HD, Hodgkin disease; MDS, myelodysplastic
syndrome; MM, multiple myeloma; MMF, mycophenolate mofetil;
MTX, methotrexate; NHL, non-Hodgkin lymphoma; PBSC, peripheralPATIENTS AND METHODS
We retrospectively analyzed data from consecutive
patients who had allogeneicHCT fromHLA-identical
sibling or HLA-matched unrelated donors for treat-
ment of hematologic malignancies between January
2001 and December 2008. All recipients and donors
had given written informed consent to treatment and
use of medical records for research according to proto-
cols approved by the institutional review board at the
Fred Hutchinson Cancer Research Center (FHCRC).
To be included in the final analysis, recipients had to
be at least 18 years old. Medication data were obtained
by retrospective review of medical records and inde-
pendently confirmed by a pharmacist. Transplant re-
cipients were considered ‘‘on statin treatment’’ if they
were treated with any statin drug at any dose for at least
3 consecutive months prior to transplant. Statin treat-
ment could be discontinued during the preparative
regimen and resumed immediately after transplant.
Data on recipient statin treatment were collected until
day 100 after transplant. Characteristics of recipients,
donors, and treatment variables are shown in Table 1.
Multivariate analyses of time-to-event endpoints
were performed using Cox regression. Death was
treated as a competing risk for analysis of relapse.
Death and relapse were treated as competing risks
for analysis of aGVHD and cGVHD. Relapse was
treated as a competing risk for the analysis of nonre-
lapse mortality (NRM). The landmark analysis was
restricted to patients still at risk to develop cGVHD
at day 100 (excluding patients who had died, relapsed,
or developed cGVHD prior to day 100). All P-values
are 2 sided.blood stem cells.
*Disease risk: ‘‘Standard’’ refers to chronic myeloid leukemia in chronic
phase, myelodysplastic syndromes without excess blasts, and leukemia
and lymphoma in remission. ‘‘High’’ refers to all other hematologic
malignancies.
†Seven patients received additional sirolimus.
‡10 patients received additional sirolimus.RESULTS AND DISCUSSION
Among the 1206 recipients included in this analy-
sis, 76 (6%) were treated with a statin at the time of
transplant (atorvastatin, 53%; simvastatin, 21%; pra-
vastatin, 13%; lovastatin, 8%; and rosuvastatin, 5%).
Fifty-two percent and 48%, respectively, had grafts
fromHLA-identical siblings and HLA-matched unre-
lated donors (Table 1). Compared to patients not
treated with a statin, those treated with a statin were
older (median age 60 years versus 52 years, P\ .001),
more frequently male (79% versus 55%, P \ .001),
recipients of unrelated grafts (63% verusus 47%,
P 5 .006), and prepared with a reduced-intensityconditioning regimen (59% versus 39%, P \ .001).
There were no significant differences between the 2
groups with respect to distributions of disease risk,
median donor age, donor sex, stem cell source, and
type of immunosuppression after transplant.
After adjustment for donor and recipient age (#50
years versus .50 years) and sex (female-into-male
versus other), donor type (related versus unrelated),
conditioning intensity (high dose versus reduced
Table 2. Multivariate Analysis for Association of Recipient Statin Use with Outcomes after Allogeneic Hematopoietic Cell




Postgrafting Cyclosporine, n 5 821
Recipients Receiving
Postgrafting Tacrolimus, n 5 385
Outcome Hazard Ratio 95% CI P Hazard Ratio 95% CI P Hazard Ratio 95% CI P
Grade II-IV GVHD 0.93 0.7-1.3 .63 0.87 0.6-1.3 .47 1.11 0.7-1.8 .68
Grade III-IV GVHD 1.17 0.6-2.1 .62 1.01 0.5-2.2 .99 1.55 0.6-4.1 .37
Chronic GVHD 0.78 0.6-1.1 .17 0.62 0.4-1.0 .05 1.15 0.7-2.0 .61
Relapse/disease progression 1.26 0.8-2.0 .34 1.75 1.0-3.0 .04 0.60 0.2-1.7 .33
Nonrelapse mortalty 0.90 0.6-1.3 .60 0.86 0.5-1.4 .54 0.97 0.5-1.8 .93
Overall mortality 0.98 0.7-1.3 .90 1.07 0.7-1.6 .71 0.86 0.5-1.5 .59
Landmark Analysis† (among recipients alive, on statin treatment, in remission, and without chronic GVHD at day 100)
n 5 863 n 5 560 n 5 303
Chronic GVHD 0.63 0.4-1.0 .06 0.40 0.2-0.9 .02 0.98 0.5-1.9 .96
Relapse/disease progression 1.76 0.9-3.3 .08 2.53 1.3-5.1 .009 0.84 0.2-3.6 .81
CI indicates confidence interval; GVHD, graft-versus-host disease.
Results were adjusted for sex-mismatch (F/M), conditioning-intensity, donor age (>50 years), patient age (>50 years), tacrolimus-based immunosup-
pression, disease risk, stem cell source, donor type, and year of transplant.
*Outcomes among recipients treated with a statin medication are compared with those among recipients whowere not treated with a statin medication
after HCT. Specifically: all recipients (n 5 76 versus n 5 1130); recipients receiving postgrafting cyclosporine (n 5 48 versus n 5 773); and recipients
receiving postgrafting tacrolimus (n 5 28 versus n 5 357).
†All recipients (n 5 38 versus n 5 863); recipients receiving postgrafting cyclosporine (n 5 22 versus n 5 560); and recipients receiving postgrafting
tacrolimus (n 5 16 versus n 5 303).
Biol Blood Marrow Transplant 16:1463-1466, 2010 1465Recipient Statin Exposure and GVHDintensity), disease risk (standard versus high), stem cell
source (mobilized blood cells versus marrow), type of
calcineurin inhibitor used after transplant (CsA versus
tacrolimus), and year of transplant inmultivariate anal-
ysis, the risks of grade II-IV and grade III-IV aGVHD,
NRM, and overall mortality were similar between re-
cipients with and without statin treatment (Table 2).
The risk of extensive cGVHD, however, was 38%
lower in recipients with statin treatment given CsA-
based immunosuppression after transplant compared
to those without statin treatment (n 5 48 versus n 5
773; hazard ratio [HR], 0.62; 95% confidence interval
[CI], 0.4-1.0; P 5 .05). In contrast, among patients
with tacrolimus-based immunosuppression after
transplant, the risk of cGVHDwas not significantly af-
fected by recipient statin use (n 5 28 versus n 5 357;
HR, 1.15; 95% CI, 0.7-2.0; P 5 .61). The incidence
of de novo onset cGVHD was similar between
statin-treated compared to nonstatin-treated recipi-
ents (16% versus 13%). Importantly, the decreased
risk of cGVHD among statin-treated recipients with
CsA-based immunosuppression was associated with
a significantly increased risk of recurrent malignancy
(multivariate HR, 1.75; 95% CI, 1.0-3.0; P 5 .04).
At day 100 after transplant, 87% of statin-treated
patients (66 of 76) were still alive. Of those, 67% con-
tinued to receive statin treatment beyond day 100. In
a landmark analysis restricted to recipients alive with-
out cGVHD, and on statin treatment on day 100 after
transplant (n 5 38), the association between statin use
and protection against cGVHD (multivariate HR,
0.40, P5 .02) or increased risk of recurrentmalignancy
(multivariate HR, 2.53, P 5 .009) among recipientswith CsA-based immunosuppression was even more
pronounced (Table 2).
The interaction between statins and CsA observed
in the current study was statistically significant
(P5 .04). Thiswas consistent with our previous analysis
among recipients of related grafts, where protection
against aGVHD mediated by donor statin use was
strongly associated with CsA-based immunosuppres-
sion [9]. This apparent effect-association between
statins and CsA was unexpected and could reflect
synergistic impairment ofT cellmitochondrial function
by both drugs, leading to compromised T cell respon-
siveness to alloantigen and establishment of tolerance
[12,13]. Alternatively, in particular, because the statin/
CsA effect-association was seen in statin-treated
recipients, it might be explained by the fact that statin
serum concentrations are considerably higher in
patients treated with CsA than in those treated with
tacrolimus [14,15]. This appears to be related to the
fact that CsA, in contrast to tacrolimus, has profound
inhibitory effects on hepatocyte membrane-
transporters known to affect statin metabolism,
including organic anion transporting peptides (OATP)
[15-17]. OATP(1B1) inhibition by CsA, but not
tacrolimus appears to be more relevant with respect to
explaining differential effects of the 2 calcineurin
inhibitors on statin levels than inhibition of
cytochrome P450(3A4) or the p-glycoprotein efflux
pump [15].
Our previous analysis of transplant outcomes ac-
cording to donor and recipient statin use after related
HCT did not show a significant association between
recipient statin use and risk of cGVHD. This lack of
1466 Biol Blood Marrow Transplant 16:1463-1466, 2010M. Rotta et al.association was possibly related to sample size limita-
tions and a differential effect size according to donor
type, because the reduction in risk of cGVHD associ-
ated with statin use in the current study was less
pronounced among related recipients (adjusted HR,
0.69; 95% CI, 0.4-1.2; P 5 .21) than unrelated
recipients (HR, 0.44; 95% CI, 0.2-1.1; P 5 .07).
The main statin-associated toxicities described in
the literature are muscular and hepatocellular injury
[18].The risk of statin toxicity is considerably increased
by the concurrent use of calcineurin inhibitors that are
thought to increase statin levels by competing with the
hepatic disposition of statins [19,20]. Therefore, the
increased risk of statin-related toxicity among allograft
recipients requiring calcineurin inhibitor-based immu-
nosuppression is a legitimate concern. Among the 76
recipients treated with statins in our study, 12 (16%)
experienced predominantly mild-to-moderate statin-
related toxicity within 90 days after transplant.We ob-
served $3-fold increases in serum aminotransferase
enzyme levels (n 5 7), myalgias without evidence of
rhabdomyolysis (n5 2), and documented rhabdomyol-
ysis (n5 3)with serum creatinine kinase levels.10,000
U/L and serum creatinine .2.0 mg/dL. Discontinua-
tion of statin treatment resulted in prompt and
complete resolution of symptoms.
In conclusion, our data suggest that recipient statin
use, which appears to be associated with manageable
toxicity, may confer protection against extensive
cGVHD, but not against aGVHD, in patients given
postgrafting CsA. In contrast, at least in related donor
HCT, donor statin use confers profound protection
against grade III-IV aGVHD without an apparent ef-
fect on cGVHD [9]. These findings can be interpreted
to suggest differential mechanisms in the pathophysiol-
ogy of aGVHD and cGVHD. If confirmed in
well-designed prospective clinical trials, GVHD-
prevention through donor statin-‘‘conditioning’’ may
become an important addition to the armamentarium
of approaches for prevention of aGVHD. The benefit
of reducing the risk of cGVHD by virtue of treating re-
cipients with statins, however, needs to be carefully
weighted against the increased risk of recurrent malig-
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